Īrija - angļu - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - telmisartan; hydrochlorothiazide - tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Īrija - angļu - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - telmisartan; hydrochlorothiazide - tablet - 80 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Īrija - angļu - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - telmisartan; hydrochlorothiazide - tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

macleods pharmaceuticals limited - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - telmisartan 40 mg - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets.  control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national commit

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Īrija - angļu - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - telmisartan; hydrochlorothiazide - tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Īrija - angļu - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - telmisartan; hydrochlorothiazide - tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Īrija - angļu - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - telmisartan; hydrochlorothiazide - tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Īrija - angļu - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - telmisartan; hydrochlorothiazide - tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics